EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen
28/06/2024 11:57
June 28 (Reuters) - ARS Pharmaceuticals SPRY.O said on
Friday the European Medicines Agency (EMA) recommended the
approval of its needle-free emergency treatment for allergic
reactions.
(Reporting by Christy Santhosh; Editing by Nivedita
Bhattacharjee)
((Christy.Santhosh@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle